<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Some ethical considerations for the &quot;off-label&quot; use of drugs such as Avastin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Wong, D; Kyle, G</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>British Journal Of Ophthalmology, 2006, v. 90 n. 10, p. 1218-1219</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2006</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/85510">http://hdl.handle.net/10722/85510</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.; British Journal of Ophthalmology. Copyright © BMJ Publishing Group.</td>
</tr>
</tbody>
</table>
Avastin: ethical considerations

Some ethical considerations for the ‘‘off-label’’ use of drugs such as Avastin

D Wong, G Kyle

Is off-label use of drugs legal?

A
day who has attended ophthalmology conferences recently cannot fail to notice the enthusiasm of ophthalmologists for Avastin. Avastin is a humanised monoclonal antibody against vascular endothelial growth factor: an important growth factor for angiogenesis. The labelled indication of Avastin is for the treatment of predominantly classic lesions.3 The National Institute for Health and Clinical Excellence (NICE) does not recommend PDT for predominantly classic lesions, except in the context of a study.4 Good evidence shows that PDT is also effective in treating small occult lesions and deteriorating vision.5 NICE has not approved this because it has not considered it. In most European countries PDT for occult lesions is approved. Equally, Macugen is a licensed and proven effective treatment, but its approval is pending an appraisal process that is not due to report for more than 12 months. In the USA, the Food and Drug Administration (FDA)-approved treatments are PDT and Macugen. A recent survey indicated that most ophthalmologists believe Avastin to be equally or more effective than the FDA-approved treatment. The American Academy of Ophthalmology has asked the insurance companies to approve and pay for Avastin, even though it is not a treatment proven by RCT (http://www.aao.org/news/release/20060420.cfm)

ETHICS AND RANDOMISED CONTROLLED TRIALS

For dramatically effective treatment, randomised trials are not necessary. Many well-known examples of such treatments exist: penicillin for bacterial infections; smallpox vaccination; thyr
tine for hypothyroidism; vitamin B12 replacement; insulin for insulin-dependent diabetes; anaesthesia for surgical operations; and the immobilisation of fractured bones. In all these examples, observational studies were adequate to show effectiveness.6 Equipoise is the only justification for randomisation. If a treatment is clearly superior, randomisation will put one group of patients at a disadvantage. Randomisation is necessary to avoid bias in case selection and interpretation of the results. In wet age-related macular degeneration (AMD), good objective measures of outcome are seen. In the UK, the only NICE-approved treatment for AMD is PDT, and this is limited to classic lesions with no occult lesions. Is it irresponsible to use an unproven treatment instead of an approved treatment? If it is not, is it ethical to perform a randomised trial of PDT versus Avastin? Some think the only ethical trial is between Lucentis and Avastin.

IS IT FAIR AND TO WHOM?

We are grateful to drug companies that have invested large amounts of research money and effort on developing new treatment. In the case of Avastin, its use initially was based on the first-year results of Lucentis.7 Avastin is in fact the mother molecule and Lucentis a fragment of this, with the active binding sites. Lucentis was developed because it was thought that Avastin would not penetrate the full thickness of the retina and might not be effective in choroidal neovascularisation.8 Case series of Avastin showed results that were comparable to Lucentis. It is difficult to estimate, but Avastin has probably been used on >10 000 patients worldwide, with few documented complications.9,10

In divided doses, Avastin may cost only a few pounds per injection. Lucentis, when licensed, is not likely to be cheap. If Herceptin or Macugen provides a guide, then the cost might be several thousands of pounds per patient per year. Both Lucentis and Avastin are produced by the same company, Genentech, San Francisco, USA. Assuming that Lucentis gets a licence in 6 months, doctors will have the dilemma of a choice between the two: with an expensive and proven treatment on the one hand and a cheap treatment with many unanswered questions on the other. Is it fair that Genentech should lose out? What of the patients (or countries) who cannot afford Lucentis? Is it fair that treatment is available to only those who are wealthy?

RIGHTS AND DUTY

No one has any right (to a treatment) unless someone else has a duty to provide it. In modern societies the duty to provide healthcare is established by law on the government. The NHS is free at the point of delivery. This does not mean that all treatments can be afforded and funded out of taxation. The courts stated that “the (European) Convention (on human rights) does not give applicants the right to free healthcare in general,” and emphasised the right of the government to determine healthcare priorities.17 No patient has any legal right to an expensive treatment until NICE recommends it and charges the primary care trusts (PCT) to fund the treatment. NICE undoubtedly needs time to appraise and consult. In the meantime, what is the duty of care of the doctor?
‘IS MY EYE TREATABLE, DOCTOR?’

To the next patient with a minimally classic lesion, what should we say?

Do we say, “No! there is no approved treatment”? Do we say, “Yes, there is a proven treatment, but you are not entitled to it as the government has not agreed to fund this expensive treatment. We can try and apply to your local health authority for funding. It is unlikely that every patient applied for will be funded.”

Or, do we say, “There is an unapproved treatment, which seems to be effective, safe and affordable, but the evidence is not of the highest order. Like any new treatments, there is no long-term safety and efficacy data.”

DUTY OF CARE: WHO CARES?

The introduction of Avastin has created a dilemma. Doctors are torn. We are constantly urged to practice evidence-based medicine. Equally importantly, doctors need to practice medicine compassionately and ethically. Difficult decisions are often reduced to simple bottomline type analyses: what would you do if the patient sitting in front of you is your mother and she is losing vision fast? The present difficulties over Avastin echo the fuss made when another apparent wonder drug, Steptomycin, was introduced for treatment of tuberculosis. There was resistance to randomisation (a novel concept then) as benefits of treatment were obvious and compelling, but randomisation won the day. The only way a patient can receive the drug was to agree to enter the trial (this in itself was ethically questionable). An exception was the case of a physician who contracted tuberculosis while the trial was still running. He was not entered into the trial but received the new drug anyway.

Some doctors opt to advise the patient to pay for the drug and to have private treatments. A few doctors genuinely try to seek research funding and mount studies to treat patients. Yet others write a case of needs, apply to hospital medicine committees, write to PCTs and plead for funding on a case-by-case basis. The work required to introduce a new treatment is substantial; the standard ethics application form is 60 pages long; a pathway of care includes several nights on the computer; a case of needs requires many meetings with managers and colleagues.

It is becoming increasingly difficult for a doctor to discharge his or her duty of care. But unless the doctor is willing to do so, who else will be the patient’s advocate?

REFERENCE


